Valneva (NASDAQ:VALN) Releases Quarterly Earnings Results, Misses Expectations By $0.32 EPS

Valneva (NASDAQ:VALN) released its quarterly earnings results on Wednesday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32), Zacks reports. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%.

Valneva Trading Up 5.5 %

NASDAQ:VALN traded up $0.37 during midday trading on Thursday, hitting $7.10. 10,924 shares of the company traded hands, compared to its average volume of 25,915. The firm’s fifty day moving average is $6.24 and its 200-day moving average is $5.60. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The firm has a market capitalization of $576.95 million, a P/E ratio of -54.88 and a beta of 1.93. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Valneva in a report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.